S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG

摘要

S*BIO Pte Ltd has become Singapore's first biotechnology company to initiate a Phase I clinical trial of a novel anti-cancer compound.The compound,SB939,belongs to a new class of targeted anti-cancer therapeutics called histone deacetylase(HDAC)inhibitors.SB93 9 is designed to be a "best-in-class" therapeutic amongst HDAC inhibitors being developed worldwide,and has demonstrated the potential to bring additional therapeutic benefits due to its high potency,superior oral availability and good tolerability.